{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T05:31:16Z","timestamp":1766467876693,"version":"3.44.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100010891","name":"Portola Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010891","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006479","name":"Cordis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006479","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1016\/j.ahj.2010.07.037","type":"journal-article","created":{"date-parts":[[2010,12,11]],"date-time":"2010-12-11T04:10:09Z","timestamp":1292040609000},"page":"1029-1034.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Fondaparinux with UnfracTionated heparin dUring Revascularization in Acute coronary syndromes (FUTURA\/OASIS 8): A randomized trial of intravenous unfractionated heparin during percutaneous coronary intervention in patients with non\u2013ST-segment elevation acute coronary syndromes initially treated with fondaparinux"],"prefix":"10.1016","volume":"160","clinical-trial-number":[{"clinical-trial-number":"nct00790907","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Philippe Gabriel","family":"Steg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shamir","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjit","family":"Jolly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denis","family":"Xavier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans-Juergen","family":"Rupprecht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Luis","family":"Lopez-Sendon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Chrolavicius","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunil V.","family":"Rao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher B.","family":"Granger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janice","family":"Pogue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiona","family":"Laing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salim","family":"Yusuf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2010.07.037_bb0005","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1161\/CIRCULATIONAHA.107.185752","article-title":"ACC\/AHA 2007 guidelines for the management of patients with unstable angina\/non-ST elevation myocardial infarction: executive summary. A report of the American College of Cardiology\/American Heart Association Task Force on practice guidelines","volume":"116","author":"Anderson","year":"2007","journal-title":"Circ"},{"key":"10.1016\/j.ahj.2010.07.037_bb0010","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/S0735-1097(02)02336-7","article-title":"ACC\/AHA 2002 guidelines update for the management of subjects with unstable angina and non-ST-segment elevation myocardial infarction\u2014summary article","volume":"40","author":"Braunwald","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2010.07.037_bb0015","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1093\/eurheartj\/ehm161","article-title":"Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. The task force for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes of the European Society of Cardiology","volume":"28","author":"Bassand","year":"2007","journal-title":"EHJ"},{"key":"10.1016\/j.ahj.2010.07.037_bb0020","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJMoa055443","article-title":"Comparison of fondaparinux and enoxaparin in acute coronary syndromes","volume":"354","author":"The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigator (OASIS 5 Investigators)","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2010.07.037_bb0025","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1016\/j.jacc.2007.07.042","article-title":"Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention","volume":"50","author":"Mehta","year":"2007","journal-title":"JACC"},{"key":"10.1016\/j.ahj.2010.07.037_bb0030","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1001\/jama.295.13.joc60038","article-title":"Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction. The OASIS-6 randomized trial","volume":"295","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2010.07.037_bb0035","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/MCA.0b013e328300426b","article-title":"In vitro comparison of fondaparinux, unfractionated heparin, and enoxaparin in preventing cardiac catheter-associated thrombus","volume":"19","author":"Schlitt","year":"2008","journal-title":"Coronary Art Dis"},{"key":"10.1016\/j.ahj.2010.07.037_bb0040","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.ahj.2006.08.002","volume":"152","author":"White","year":"2006","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2010.07.037_bb0045","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1056\/NEJMoa052711","article-title":"Enoxaparin versus unfarctionated heparin in elective percutaneous coronary intervention","volume":"355","author":"Montalescot","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2010.07.037_bb0050","first-page":"1","article-title":"Catheter-related thrombosis: biological and clinical evidence for risk with currently available anticoagulants","author":"Montalescot","year":"2009","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.ahj.2010.07.037_bb0055","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1093\/eurheartj\/ehi138","article-title":"Guidelines for percutaneous coronary interventions. The task force for percutaneous coronary interventions of the European Society of Cardiology","volume":"26","author":"Silber","year":"2005","journal-title":"EHJ"},{"key":"10.1016\/j.ahj.2010.07.037_bb0060","first-page":"261","article-title":"Focused update of the ACC\/AHA\/SCAI 2005 guideline update for percutaneous coronary intervention","author":"King","year":"2007","journal-title":"Circ 2008;117"},{"key":"10.1016\/j.ahj.2010.07.037_bb0065","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1378\/chest.126.3_suppl.576S","article-title":"Antithrombotic therapy during percutaneous coronary intervention: the seventh ACCP conference on antithrombotic and thrombolytic therapy","volume":"126","author":"Popma","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.ahj.2010.07.037_bb0070","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/S0735-1097(02)02767-5","article-title":"Relationship between heparin anticoagulation and clinical outcomes in coronary stent intervention","volume":"41","author":"Tolleson","year":"2003","journal-title":"JACC"},{"key":"10.1016\/j.ahj.2010.07.037_bb0075","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1161\/01.CIR.0000139868.53594.24","article-title":"Relationship between activated clotting time and ischemic or hemorrhagic complications","volume":"110","author":"Brener","year":"2004","journal-title":"Circ"},{"key":"10.1016\/j.ahj.2010.07.037_bb0080","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1093\/oxfordjournals.eurheartj.a015308","article-title":"A randomized trial of a fixed high dose versus a weight-adjusted low dose of intravenous heparin during coronary angioplasty","volume":"18","author":"Boccara","year":"1997","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2010.07.037_bb0085","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1136\/heart.88.4.331","article-title":"Heparin dose during percutaneous coronary intervention: how low dare we go?","volume":"88","author":"Niccoli","year":"2002","journal-title":"Heart"},{"key":"10.1016\/j.ahj.2010.07.037_bb0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0002-9149(02)02988-0","article-title":"Efficacy and safety of minimal dose (\u22641000 Units) unfractionated heparin with abciximab in percutaneous coronary intervention","volume":"91","author":"Denardo","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2010.07.037_bb0095","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.106.685313","article-title":"Academic research consortium. Clinical end points in coronary stent trials: a case for standardized definitions","volume":"115","author":"Cutlip","year":"2007","journal-title":"Circulation"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870310007301?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870310007301?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T05:42:38Z","timestamp":1757569358000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870310007301"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["S0002870310007301"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2010.07.037","relation":{},"ISSN":["0002-8703"],"issn-type":[{"type":"print","value":"0002-8703"}],"subject":[],"published":{"date-parts":[[2010,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fondaparinux with UnfracTionated heparin dUring Revascularization in Acute coronary syndromes (FUTURA\/OASIS 8): A randomized trial of intravenous unfractionated heparin during percutaneous coronary intervention in patients with non\u2013ST-segment elevation acute coronary syndromes initially treated with fondaparinux","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2010.07.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}